临床专家主导的产品上市 · CDMO尽职调查 · 市场决策
商业化情报中心
7 针对临床专家品牌膳食补充剂与特医食品项目的决策指南。在向CDMO简报前，帮助您厘清合适的工作范围。
⌘K以搜索任意指南
7
已发布指南
4
上市领域
4
尽职调查领域
2
决策模型
在向 CDMO 提交简报之前
上市决策
在开发开始之前，指导您做出决定产品范围、市场路径和商业准备状态的关键决策。
Launch Strategy
From clinician thesis to a governed product decision
Market Access & Regulatory
Markets, product category and evidence boundaries
Formulation & Scale-Up
Technical choices that determine manufacturability
Clinician-Branded Products
Patient trust, evidence and brand responsibility
循证决策
尽职调查
用于评估CDMO契合度、质量体系、IP边界及技术转移就绪度的框架，拒绝将复杂的决策简化为勾选清单。
精选决策指南
精选指南
Formulation & Scale-Up
Navigating Lifecycle Impairment Mechanisms for Dietary Supplements and Functional Foods: From Formulation to Systemic Exposure
Buyers face significant risk from diverse formulation, processing, and physiological mechanisms that measurably impair the identity, potency, release, bioaccessibility, systemic exposure, or safety of dietary supplements and functional foods. This can lead to reduced efficacy and commercial failure if not addressed across the product lifecycle.
≈ 38 分钟阅读
Formulation & Scale-Up
Optimizing Multi-Strain Probiotic Formulations: Addressing Viability, Delivery, and Efficacy Challenges
The formulation challenge is preventing significant strain-level viability loss and compromised clinical efficacy in multi-strain probiotics. Buyers must address degradation from moisture, manufacturing, and GI transit.
≈ 36 分钟阅读
Formulation & Scale-Up
Optimizing Lipophilic Active Softgels: Managing Oxidation, Stability, and Bioavailability Through Formulation and Packaging
Ensuring the long-term chemical and physical stability, dissolution performance, and oral bioavailability of lipophilic actives in softgels is challenged by complex interactions between fill composition, shell material, packaging, and supply-chain conditions.
≈ 33 分钟阅读
上市策略
膳食补充剂制造时间表：从产品简报到首个商业批次的关键路径
买方的主要风险在于未预先明确关键产品、市场及法规参数即盲目承诺上市时间表、功效宣称或配方，进而导致高昂的返工成本或错失市场机遇。
≈ 5 分钟阅读
上市策略
在重点市场推出临床医生品牌的膳食补充剂与医学营养产品
首要挑战在于跨不同市场对临床医生品牌产品进行准确的法规分类，明确区分常规补充剂与医学营养品，这直接决定了功效声明及上市路径。
≈ 5 分钟阅读
最新研究
最新出版物
按日期排序的最新发布的买家决策指南。
Formulation & Scale-Up
Navigating Lifecycle Impairment Mechanisms for Dietary Supplements and Functional Foods: From Formulation to Systemic Exposure
Buyers face significant risk from diverse formulation, processing, and physiological mechanisms that measurably impair the identity, potency, release, bioaccessibility, systemic exposure, or safety of dietary supplements and functional foods. This can lead to reduced efficacy and commercial failure if not addressed across the product lifecycle.
≈ 38 分钟阅读
Formulation & Scale-Up
Optimizing Multi-Strain Probiotic Formulations: Addressing Viability, Delivery, and Efficacy Challenges
The formulation challenge is preventing significant strain-level viability loss and compromised clinical efficacy in multi-strain probiotics. Buyers must address degradation from moisture, manufacturing, and GI transit.
≈ 36 分钟阅读
Formulation & Scale-Up
Optimizing Lipophilic Active Softgels: Managing Oxidation, Stability, and Bioavailability Through Formulation and Packaging
Ensuring the long-term chemical and physical stability, dissolution performance, and oral bioavailability of lipophilic actives in softgels is challenged by complex interactions between fill composition, shell material, packaging, and supply-chain conditions.
≈ 33 分钟阅读
上市策略
膳食补充剂制造时间表：从产品简报到首个商业批次的关键路径
买方的主要风险在于未预先明确关键产品、市场及法规参数即盲目承诺上市时间表、功效宣称或配方，进而导致高昂的返工成本或错失市场机遇。
≈ 5 分钟阅读
上市策略
在重点市场推出临床医生品牌的膳食补充剂与医学营养产品
首要挑战在于跨不同市场对临床医生品牌产品进行准确的法规分类，明确区分常规补充剂与医学营养品，这直接决定了功效声明及上市路径。
≈ 5 分钟阅读
市场准入与监管合规
迪拜产品上市指南：保健补充剂与医用食品的分类界定
进入迪拜市场的主要风险在于将本应归类为特殊医学用途配方食品（FSMP）的产品误分类为保健补充剂，从而导致监管延误、驳回及产品重新设计。这一关键决策将直接影响产品架构、预期用途声明、渠道策略以及所需的证据包。
≈ 5 分钟阅读
按字母排序的参考索引
完整商业化指南索引
7 买方决策指南 — 选择任意标题以打开完整简报。
Navigating Lifecycle Impairment Mechanisms for Dietary Supplements and Functional Foods: From Formulation to Systemic Exposure
Formulation & Scale-Up
Optimizing Lipophilic Active Softgels: Managing Oxidation, Stability, and Bioavailability Through Formulation and Packaging
Formulation & Scale-Up
Optimizing Multi-Strain Probiotic Formulations: Addressing Viability, Delivery, and Efficacy Challenges
Formulation & Scale-Up
全球医用食品与FSMP市场准入：监管路径与商业策略解析
市场准入与监管
在重点市场推出临床医生品牌的膳食补充剂与医学营养产品
上市策略
膳食补充剂制造时间表：从产品简报到首个商业批次的关键路径
上市策略
迪拜产品上市指南：保健补充剂与医用食品的分类界定
市场准入与监管合规
商业化情报
本中心是什么 —— 以及不是什么
Commercialization Intelligence Hub 是 Olympia Biosciences 针对临床主导型和高端健康品牌的公开决策支持库。它帮助潜在合作伙伴在编写开发简报之前，明确需要解决的核心问题。
Paid Discovery 之前的决策支持
这些指南将公开的市场、监管和技术考量转化为决策框架。它们不发布配方、报价或定制化开发建议。
一份有用的指南能够阐明必须做出哪些决策、应当索取哪些证据，以及何时将该问题纳入限定范围的 Paid Discovery 合作中。
我们发布此资料库旨在使首次商务洽谈更加精准，节省开发时间，并帮助严肃的买家带着正确的简报前来。
共建下一期买家指南
产品上市或尽职调查需要专业指南？
请告诉我们需要澄清的市场准入或 CDMO 尽职调查问题。我们会审查相关议题以用于未来的买方指南；具体的产品决策则属于定制化的 Paid Discovery 服务范围。
✓ 免费方向指导 ✓ 由 Olympia Biosciences 审查 ✓ 定制化决策属于 Paid Discovery 的服务范畴
商业化简报
全新商业化情报简报
获取 Olympia Biosciences 针对临床主导型及高端健康品牌的最新上市、监管及 CDMO 决策洞察。
无垃圾信息。随时可取消订阅。每周发送一封。
APPLY THIS INTELLIGENCE